Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Analysts at Zacks Research lifted their Q3 2025 earnings per share estimates for Pacira BioSciences in a research report issued to clients and investors on Thursday, May 29th. Zacks Research analyst R. Department now expects that the company will earn $0.44 per share for the quarter, up from their prior estimate of $0.42. The consensus estimate for Pacira BioSciences' current full-year earnings is $2.41 per share.
A number of other equities analysts also recently commented on the stock. HC Wainwright upped their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research note on Tuesday, April 8th. Barclays increased their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Finally, Needham & Company LLC dropped their price objective on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $26.44.
Check Out Our Latest Research Report on PCRX
Pacira BioSciences Trading Down 0.9%
Shares of NASDAQ PCRX traded down $0.24 during mid-day trading on Monday, reaching $26.74. The company had a trading volume of 677,245 shares, compared to its average volume of 972,554. The business's 50-day moving average is $25.45 and its 200-day moving average is $23.19. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -13.17 and a beta of 0.56. Pacira BioSciences has a 52 week low of $11.16 and a 52 week high of $30.39.
Hedge Funds Weigh In On Pacira BioSciences
A number of hedge funds and other institutional investors have recently modified their holdings of PCRX. Alyeska Investment Group L.P. bought a new stake in Pacira BioSciences during the 1st quarter valued at $32,506,000. Point72 Asset Management L.P. bought a new stake in Pacira BioSciences during the fourth quarter valued at about $20,266,000. American Century Companies Inc. boosted its position in Pacira BioSciences by 392.2% during the first quarter. American Century Companies Inc. now owns 667,423 shares of the company's stock valued at $16,585,000 after purchasing an additional 531,831 shares in the last quarter. Nuveen LLC bought a new stake in Pacira BioSciences during the first quarter valued at about $12,884,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Pacira BioSciences during the fourth quarter valued at about $8,558,000. 99.73% of the stock is currently owned by institutional investors.
About Pacira BioSciences
(
Get Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
See Also
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
